Profile
Jon S.
Kuwahara worked as a Director at EMI Holding, Inc. and Emmaus Life Sciences, Inc. He also worked as an Assistant Controller at Questcor Pharmaceuticals, Inc. and as a Controller at Avanir Pharmaceuticals, Inc. Additionally, he served as a Vice President-Finance at Espero Pharmaceuticals, Inc. and as a CAO & SVP-Finance & Administration at Eledon Pharmaceuticals, Inc. Kuwahara received an undergraduate degree from the University of Hawai'i at Hilo.
Former positions of Jon S. Kuwahara
Companies | Position | End |
---|---|---|
ELEDON PHARMACEUTICALS, INC. | Chief Executive Officer | 2020-09-08 |
Espero Pharmaceuticals, Inc.
Espero Pharmaceuticals, Inc. Medical DistributorsDistribution Services Espero Pharmaceuticals, Inc. is a pharmaceutical company that specializes in developing therapeutics for unmet needs in thrombosis and cardiac rhythm control. Espero Pharmaceuticals is based in Jacksonville, FL and has subsidiaries in the United States. The private company's portfolio includes tecarfarin, which is used for patients requiring anticoagulation, and a novel candidate for treating arrhythmias. The company was founded by Jeffrey S. Cole and Quang X. Pham. | Corporate Officer/Principal | 2017-05-31 |
AVANIR PHARMACEUTICALS INC | Comptroller/Controller/Auditor | 2016-05-31 |
QUESTCOR PHARMACEUTICALS INC | Corporate Officer/Principal | 2014-09-30 |
EMMAUS LIFE SCIENCES, INC. | Director/Board Member | - |
Training of Jon S. Kuwahara
University of Hawai'i at Hilo | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ELEDON PHARMACEUTICALS, INC. | Health Technology |
EMMAUS LIFE SCIENCES, INC. | Health Technology |
Private companies | 4 |
---|---|
Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
Questcor Pharmaceuticals, Inc.
Questcor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Questcor Pharmaceuticals, Inc. was engaged in development, marketing and sale of prescription drugs. It operated as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product was H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and was headquartered in Anaheim, CA. | Health Technology |
EMI Holding, Inc.
EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Health Technology |
Espero Pharmaceuticals, Inc.
Espero Pharmaceuticals, Inc. Medical DistributorsDistribution Services Espero Pharmaceuticals, Inc. is a pharmaceutical company that specializes in developing therapeutics for unmet needs in thrombosis and cardiac rhythm control. Espero Pharmaceuticals is based in Jacksonville, FL and has subsidiaries in the United States. The private company's portfolio includes tecarfarin, which is used for patients requiring anticoagulation, and a novel candidate for treating arrhythmias. The company was founded by Jeffrey S. Cole and Quang X. Pham. | Distribution Services |
- Stock Market
- Insiders
- Jon S. Kuwahara